SciSparc secures FDA approval for Phase IIb clinical trial of SCI-110, targeting unmet needs in Tourette Syndrome, Global trial begins soon.

Drug developers are pursuing a new option for reproductive care in the post-Roe landscape: birth control pills for men. Why ...

In Q2, it brought in $11.3 billion in sales, 36% higher than a year prior, and it cranked up its annual revenue guidance for ...

Among biopharma firms, size didn’t always correlate with the highest wages, a recently debuted analysis of ‘best’ pharma ...

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

Piramal Pharma Solutions Inc. today announced plans to expand its current Lexington operations with a nearly $80 million ...

Piramal's global Contract Development and Manufacturing Organization plans to more than double the facility’s capacity by Q1 ...

Having banked $60 million from Eli Lilly in the spring, Aktis Oncology has now closed an upsized $175 million series B that ...

BridgeBio Pharma shared new data showing that acoramidis reduced mortality and cardiovascular hospitalizations by 42% in its Phase 3 ATTRibute-CM study for ATTR-CM. FDA decision expected in November ...

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on BridgeBio Pharma (BBIO – Research Report) today and set a price target ...

Analyst Kostas Biliouris of BMO Capital maintained a Hold rating on BridgeBio Pharma (BBIO – Research Report), retaining the price target ...

As the efficiency and efficacy of injectable treatment options improve, more patients are expected to benefit from advanced therapies.